---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-125413"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:15:10.938315+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025

## Summary
- Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.
- R&D expenses $9.2M vs $11.9M YoY; G&A $18.5M vs $18.2M YoY.
- Raised ~$61M in gross proceeds: $25M at Citius Pharma, $36M at Citius Oncology (CTOR).
- LYMPHIR launched in U.S. December 2025 for CTCL; secured NCCN Category 2A and HCPCS J-code.
- Cash and equivalents $4.3M at Sep 30, 2025; continued FDA engagement on Mino-Lok and Halo-Lido.

## SEC filing metadata
- accession: 0001213900-25-125413
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/0001213900-25-125413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/ea0270776-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-125413
- JSON: https://secwatch.observer/filing/0001213900-25-125413.json
- Plain text: https://secwatch.observer/filing/0001213900-25-125413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.